NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vivace Therapeutics

Vivace Therapeutics

Private
San Mateo, CaliforniaHealthcare & Life Scienceshttps://vivacetherapeutics.com/

Last Round

Series D

Mar 12, 2025

Est. Valuation

$125M

Total Funding Raised

$105M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Vivace Therapeutics is a biotechnology company that develops small molecule cancer therapies targeting the Hippo-YAP signaling pathway.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

small-molecule inhibitorTEAD inhibitorHippo-YAP pathwayoncologymesotheliomabiotechclinical-stageorphan drug designationODDsolid tumordrug discoverytargeted therapyclinical trialbiopharmapipeline drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vivace Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Vivace Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Vivace Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DMar 12, 2025
Series CDec 16, 2020
Series BJun 28, 2017
Series AJan 20, 2015

Key People

Founding team and executive leadership

Craig Gibbs

Chief Executive Officer

Executive Team

Vivace Therapeutics Investors

Notable investors and investment history

Vivace Therapeutics investors
InvestorRounds
RA Capital ManagementSeries C, Series D
Boxer CapitalSeries C
BioInnovation CapitalSeries B
WuXi Healthcare VenturesSeries B, Series A
Sequoia CapitalSeries C
Cenova CapitalSeries C, Series D, Series B
HongShanSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 20, 2026

    Monthly visitors increased 49% MoM.

  • Mar 12, 2025

    $35M round completed.

Vivace Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vivace Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vivace Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Mateo, California
Employee Range13
Year Founded2014
Last FundingMar 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.